Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).
Egbert F. Smit
No relevant relationships to disclose
Radj Gervais
No relevant relationships to disclose
Caicun Zhou
Consultant or Advisory Role - Boehringer Ingelheim; Lilly; Roche
Honoraria - Boehringer Ingelheim; Lilly; Roche
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Roche
Ji Feng Feng
No relevant relationships to disclose
Salih Zeki Guclu
Research Funding - Dr Suat Seren Gogus Hastaliklari Hastanesi
Mathias Hoiczyk
No relevant relationships to disclose
Elena Dorokhova
Employment or Leadership Position - Roche
Ulrich Freudensprung
Employment or Leadership Position - Roche
Pablo Diego Perez-Moreno
Employment or Leadership Position - Roche
Martin Reck
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Pfizer; Roche